Hogerzeil SJ, Hoek HW, van Hemert AM. The impact of study design on schizophrenia incidence estimates: a systematic review of Northern European studies 2008-2019. Schizophr Res. 2021;231:134–41. https://doi.org/10.1016/j.schres.2021.03.017.

Article  PubMed  Google Scholar 

Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020;8:Cd008016 https://doi.org/10.1002/14651858.CD008016.pub3.

Article  PubMed  Google Scholar 

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77. https://doi.org/10.1016/s2215-0366(19)30416-x.

Article  PubMed  PubMed Central  Google Scholar 

Zanelli J, Mollon J, Sandin S, Morgan C, Dazzan P, Pilecka I, et al. Cognitive change in schizophrenia and other psychoses in the decade following the first episode. Am J Psychiatry. 2019;176:811–9. https://doi.org/10.1176/appi.ajp.2019.18091088.

Article  PubMed  Google Scholar 

Harvey PD, Isner EC. Cognition, social cognition, and functional capacity in early-onset schizophrenia. Child Adolesc Psychiatr Clin N Am. 2020;29:171–82. https://doi.org/10.1016/j.chc.2019.08.008.

Article  PubMed  Google Scholar 

Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SO, Østergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131:185–96. https://doi.org/10.1111/acps.12374.

Article  CAS  PubMed  Google Scholar 

Müller N. Neuroprogression in schizophrenia and psychotic disorders: the possible role of inflammation. Mod Trends Pharmacopsychiatry. 2017;31:1–9. https://doi.org/10.1159/000470802.

Article  PubMed  Google Scholar 

Müller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018;44:973–82. https://doi.org/10.1093/schbul/sby024.

Article  PubMed  PubMed Central  Google Scholar 

Comer AL, Carrier M, Tremblay M, Cruz-Martín A. The inflamed brain in schizophrenia: the convergence of genetic and environmental risk factors that lead to uncontrolled neuroinflammation. Front Cell Neurosci. 2020;14:274. https://doi.org/10.3389/fncel.2020.00274.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fond G, Lançon C, Korchia T, Auquier P, Boyer L. The Role of Inflammation in the Treatment of Schizophrenia. Front Psychiatry. 2020;11:160. https://doi.org/10.3389/fpsyt.2020.00160.

Article  PubMed  PubMed Central  Google Scholar 

Miller BJ, Goldsmith DR. Evaluating the hypothesis that schizophrenia is an inflammatory disorder. Focus. 2020;18:391–401. https://doi.org/10.1176/appi.focus.20200015.

Article  PubMed  PubMed Central  Google Scholar 

van Mierlo HC, Schot A, Boks MPM, de Witte LD. The association between schizophrenia and the immune system: review of the evidence from unbiased ‘omic-studies. Schizophr Res. 2020;217:114–23. https://doi.org/10.1016/j.schres.2019.05.028.

Article  PubMed  Google Scholar 

Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine alterations in schizophrenia: an updated review. Front Psychiatry. 2019;10:892. https://doi.org/10.3389/fpsyt.2019.00892.

Article  PubMed  PubMed Central  Google Scholar 

Reale M, Costantini E, Greig NH. Cytokine imbalance in schizophrenia. From research to clinic: potential implications for treatment. Front Psychiatry. 2021;12:536257. https://doi.org/10.3389/fpsyt.2021.536257.

Article  PubMed  PubMed Central  Google Scholar 

Wu ZW, Yu HH, Wang X, Guan HY, Xiu MH, Zhang XY. Interrelationships between oxidative stress, cytokines, and psychotic symptoms and executive functions in patients with chronic schizophrenia. Psychosomatic Med. 2021;83:485–91. https://doi.org/10.1097/psy.0000000000000931.

Article  CAS  Google Scholar 

Vidal PM, Pacheco R. The cross-talk between the dopaminergic and the immune system involved in schizophrenia. Front Pharmacol. 2020;11:394. https://doi.org/10.3389/fphar.2020.00394.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trossbach SV, Hecher L, Schafflick D, Deenen R, Popa O, Lautwein T, et al. Dysregulation of a specific immune-related network of genes biologically defines a subset of schizophrenia. Translational psychiatry. 2019;9:156. https://doi.org/10.1038/s41398-019-0486-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller N. Immunology of schizophrenia. Neuroimmunomodulation. 2014;21:109–16. https://doi.org/10.1159/000356538.

Article  CAS  PubMed  Google Scholar 

Sperner-Unterweger B, Fuchs D. Schizophrenia and psychoneuroimmunology: an integrative view. Curr Opin Psychiatry. 2015;28:201–6. https://doi.org/10.1097/yco.0000000000000153.

Article  PubMed  Google Scholar 

Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019;49:2307–19. https://doi.org/10.1017/s0033291719001995.

Article  PubMed  PubMed Central  Google Scholar 

Cho M, Lee TY, Kwak YB, Yoon YB, Kim M, Kwon JS. Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Aust N Z J Psychiatry. 2019;53:742–59. https://doi.org/10.1177/0004867419835028.

Article  PubMed  Google Scholar 

Jeppesen R, Christensen RHB, Pedersen EMJ, Nordentoft M, Hjorthøj C, Köhler-Forsberg O, et al. Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - a comprehensive systematic review and meta-analysis. Brain Behav Immun. 2020;90:364–80. https://doi.org/10.1016/j.bbi.2020.08.028.

Article  CAS  PubMed  Google Scholar 

Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71:520–7. https://doi.org/10.4088/JCP.09m05117yel.

Article  CAS  PubMed  Google Scholar 

Müller N. COX-2 inhibitors, aspirin, and other potential anti-inflammatory treatments for psychiatric disorders. Front Psychiatry. 2019;10:375. https://doi.org/10.3389/fpsyt.2019.00375.

Article  PubMed  PubMed Central  Google Scholar 

Schmidt L, Phelps E, Friedel J, Shokraneh F. Acetylsalicylic acid (aspirin) for schizophrenia. Cochrane Database Syst Rev. 2019;8:Cd012116. https://doi.org/10.1002/14651858.CD012116.pub2.

Article  PubMed  Google Scholar 

Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138–49. https://doi.org/10.4088/JCP.08m04666yel.

Article  CAS  PubMed  Google Scholar 

Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26:1185–93. https://doi.org/10.1177/0269881112444941.

Article  CAS  PubMed  Google Scholar 

Zhang L, Zheng H, Wu R, Kosten TR, Zhang XY, Zhao J. The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. Schizophr Res. 2019;212:92–8. https://doi.org/10.1016/j.schres.2019.08.005x.

Article  PubMed  Google Scholar 

Krynicki CR, Dazzan P, Pariante CM, Barnes NM, Vincent RC, Roberts A, et al. Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain Behav Immunity. 2021;91:498–504. https://doi.org/10.1016/j.bbi.2020.10.026.

Article  CAS  Google Scholar 

Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40:181–91. https://doi.org/10.1093/schbul/sbt139.

Article  PubMed  Google Scholar 

Watkins CC, Andrews SR. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophr Res. 2016;176:14–22. https://doi.org/10.1016/j.schres.2015.07.018.

Article  PubMed  Google Scholar 

Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159:1029–34. https://doi.org/10.1176/appi.ajp.159.6.1029.

Article  PubMed  Google Scholar 

Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010;121:118–24. https://doi.org/10.1016/j.schres.2010.04.015.

Article  PubMed  Google Scholar 

Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry. 2005;57:1594–6. https://doi.org/10.1016/j.biopsych.2005.02.024.

Article